Introduction Secondary hyperparathyroidism (SHPT) affects bone metabolism and may lead
to bone fragility. However, there is conflicting evidence as to whether parathyroid hormone …

People with chronic kidney disease (CKD) are at increased risk of fractures in comparison to
the non-CKD population and fractures are associated with high mortality and worsening …

Chronic kidney disease-induced secondary hyperparathyroidism (CKD-SHPT) heightens
fracture risk through impaired mineral homeostasis and elevated levels of uremic toxins …

Calcitriol and calcimimetics are used to treat hyperparathyroidism secondary to chronic
kidney disease (CKD). Calcitriol administration and the subsequent increase in serum …

Background/Objectives: Chronic kidney disease and mineral bone disorders (CKD-MBD)
are frequently associated with an increased risk of both vascular calcifications (VCs) and …

Introduction This study aimed to assess the effectiveness of calcimimetics in reducing the
risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT). Material …

Calcimimetics are a class of drugs that activate the calcium-sensing receptor leading to
suppression of parathyroid hormone (PTH) production, generally used for the management …

Reducing Elevated Parathyroid Hormone to Protect Bone Strength in End-Stage Kidney
Disease Reducing Elevated Parathyroid Hormone to Protect Bone Strength in End-Stage …

Objective: Chronic kidney disease (CKD) with secondary hyperparathyroidism (SHPT)
increases the risk of fragility fractures with deterioration of cortical and trabecular bone …

Calcium, Phosphate and Bones: How Bone and Mineral Metabolism Is Altered in Kidney
Disease | SpringerLink Skip to main content Advertisement Springer Nature Link Account Menu …